Seres Therapeutics (MCRB) Return on Equity (2016 - 2025)
Historic Return on Equity for Seres Therapeutics (MCRB) over the last 11 years, with Q2 2025 value amounting to 3.35%.
- Seres Therapeutics' Return on Equity rose 29800.0% to 3.35% in Q2 2025 from the same period last year, while for Jun 2025 it was 3.35%, marking a year-over-year increase of 29800.0%. This contributed to the annual value of 8.1% for FY2024, which is 36200.0% down from last year.
- As of Q2 2025, Seres Therapeutics' Return on Equity stood at 3.35%, which was up 29800.0% from 4.14% recorded in Q1 2025.
- In the past 5 years, Seres Therapeutics' Return on Equity registered a high of 10.68% during Q1 2023, and its lowest value of 8.67% during Q3 2023.
- In the last 5 years, Seres Therapeutics' Return on Equity had a median value of 0.47% in 2021 and averaged 0.3%.
- In the last 5 years, Seres Therapeutics' Return on Equity surged by 114900bps in 2023 and then crashed by -112100bps in 2024.
- Over the past 5 years, Seres Therapeutics' Return on Equity (Quarter) stood at 0.42% in 2021, then crashed by -1011bps to 4.67% in 2022, then skyrocketed by 126bps to 1.23% in 2023, then soared by 444bps to 6.68% in 2024, then plummeted by -50bps to 3.35% in 2025.
- Its last three reported values are 3.35% in Q2 2025, 4.14% for Q1 2025, and 6.68% during Q4 2024.